Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc CORAL Study Topline Results Conference Call Transcript

Feb 16, 2022 / 01:00PM GMT
Release Date Price: €37.83 (-1.71%)
Operator

Good morning, everyone, and welcome to the Sage Therapeutics conference call to discuss topline results from the CORAL Study. (Operator Instructions) This call is being webcast live on Investors and Media section of Sage website at sagerx.com.

This call is the property of Sage Therapeutics, and recording. Reproduction or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.

I would now like to introduce Helen Rubinstein, Director of Investor Relations at Sage.

Helen Rubinstein
Sage Therapeutics, Inc. - IR Officer

Good morning, and thank you for joining Sage Therapeutics conference call to discuss topline results from the CORAL Study of zuranolone in major depressive disorder. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com where you can find the press release and slides related to today's call.

I'll point out that we will be making forward-looking statements, which are based

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot